Impact of COVID-19 on peripheral stem cell collection and preservation at a hematopoietic cell transplant center in India: Experience 2020.

Rizwan Javed, Mita Roychowdhury, Saurabh Bhave, Arijit Nag, Jeevan Kumar, Vivek Radhakrishnan, Sanjay Bhattacharya, Deepak Kumar Mishra, Niharendu Ghara, Reghu Rs, Reena Nair, Mammen Chandy
{"title":"Impact of COVID-19 on peripheral stem cell collection and preservation at a hematopoietic cell transplant center in India: Experience 2020.","authors":"Rizwan Javed,&nbsp;Mita Roychowdhury,&nbsp;Saurabh Bhave,&nbsp;Arijit Nag,&nbsp;Jeevan Kumar,&nbsp;Vivek Radhakrishnan,&nbsp;Sanjay Bhattacharya,&nbsp;Deepak Kumar Mishra,&nbsp;Niharendu Ghara,&nbsp;Reghu Rs,&nbsp;Reena Nair,&nbsp;Mammen Chandy","doi":"10.31547/bct-2021-004","DOIUrl":null,"url":null,"abstract":"<p><p>The prevailing corona virus disease 19 (COVID-19) pandemic has adversely affected the healthcare services globally. Hematopoietic cell transplantation (HCT) is considered as the preferred treatment option for several hematological malignancies, and HPC collection facilities have to function continuously along with implementing safety measures. Based on the national and international guidelines, we implemented additional measures and modifications to our standard operating procedure (SOP) to ensure secure HPC collection from patients as well as donors. Here, we report our experience with HPC collection and processing from 1st January, 2020 until 31st December, 2020. We collected 59 HPC products through apheresis and 41 cryopreservation procedures. Compared to 2019, there was a 33% decrease in the number of HPC transplants and 31% reduction in HPC collection procedures. However, we report an 86% (13 procedures) increase in the cryopreservation of HPC products from related donors, as several organizations recommend cryopreservation of HPC products. We report our institutional experience to better understand the impact of COVID-19 on HCT services in a tertiary care center in the developing world. It may also help in being prepared for any future waves of COVID-19 cases.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"4 4","pages":"84-87"},"PeriodicalIF":0.0000,"publicationDate":"2021-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d3/77/2432-7026-4-4-0084.PMC9847266.pdf","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood cell therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31547/bct-2021-004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

Abstract

The prevailing corona virus disease 19 (COVID-19) pandemic has adversely affected the healthcare services globally. Hematopoietic cell transplantation (HCT) is considered as the preferred treatment option for several hematological malignancies, and HPC collection facilities have to function continuously along with implementing safety measures. Based on the national and international guidelines, we implemented additional measures and modifications to our standard operating procedure (SOP) to ensure secure HPC collection from patients as well as donors. Here, we report our experience with HPC collection and processing from 1st January, 2020 until 31st December, 2020. We collected 59 HPC products through apheresis and 41 cryopreservation procedures. Compared to 2019, there was a 33% decrease in the number of HPC transplants and 31% reduction in HPC collection procedures. However, we report an 86% (13 procedures) increase in the cryopreservation of HPC products from related donors, as several organizations recommend cryopreservation of HPC products. We report our institutional experience to better understand the impact of COVID-19 on HCT services in a tertiary care center in the developing world. It may also help in being prepared for any future waves of COVID-19 cases.

Abstract Image

Abstract Image

2019冠状病毒病对印度造血细胞移植中心外周血干细胞采集和保存的影响:体验2020
当前流行的冠状病毒病19 (COVID-19)大流行对全球卫生保健服务产生了不利影响。造血细胞移植(HCT)被认为是几种血液系统恶性肿瘤的首选治疗方案,造血细胞收集设施必须在实施安全措施的同时持续运行。根据国家和国际指导方针,我们对标准操作程序(SOP)实施了额外的措施和修改,以确保从患者和献血者那里安全收集HPC。在此,我们报告了2020年1月1日至2020年12月31日期间我们在HPC收集和处理方面的经验。我们收集了59个HPC产品,通过分离和41个冷冻保存程序。与2019年相比,HPC移植数量减少了33%,HPC收集程序减少了31%。然而,我们报告了来自相关供体的HPC产品冷冻保存增加了86%(13个程序),因为一些组织推荐HPC产品冷冻保存。我们报告了我们的机构经验,以便更好地了解COVID-19对发展中国家三级医疗中心HCT服务的影响。它还可能有助于为未来的任何COVID-19病例浪潮做好准备。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信